Reimagining Care for Neurodegenerative Diseases
While there are a plethora of care-at-home offerings available to help patients manage chronic conditions such as heart failure, diabetes and asthma, those that treat challenging neurological conditions are few and far between. Our use of digital biomarkers and artificial intelligence to personalize each patient’s treatment is our superpower. We also help patients through our clinical services: MCI is a symptomatic diagnosis, meaning we usually don’t know the etiology because it is too early to know. The symptoms could be caused by Alzheimer’s disease or another neurodegenerative disease; or they could be due to depression, cardiovascular disease or stroke, etc. Our offering is broad enough to encompass evidence-based treatments for all of these etiologies. Neuroglee’s technology uses engaging gamification techniques and cognitive tasks on a smartphone or tablet. Patients’ performance on these games and tasks enable clinicians to assess cognitive function and intervene either through virtual visits or by adjusting the digital therapy. The technology identifies what is working for a specific patient— both from a patient satisfaction/engagement perspective and based on clinical effectiveness. We track relevant metrics related to cognitive function, mood and behavior, which are tied to automations that personalize the patient’s digital therapy accordingly. For example, adjustments will be made to the number and type of tasks and games that are offered, based on the speed of the patient’s finger movements, time to complete games or tasks, and their facial expression identified through the device camera.
Aniket Singh Rajput, CEO and founder of Neuroglee, founded the company based on an untapped opportunity to disrupt healthcare and pharma by offering an artificial intelligence and machine learning-based technology solution that can supplement drugs prescribed for MCI due to conditions such as Alzheimer’s. This need is great, since 5.7 million Americans and 50 million people worldwide are living with Alzheimer's disease, and there are very few pharmacotherapies on the market that are effective for this condition. In addition, until Neuroglee, doctors, patients and families also had very few non-pharmacotherapy options to treat MCI. Neuroglee’s solution is focused on intervening early, when patients first develop MCI, which has the potential to preserve functioning longer and teach patients the skills they need to better manage daily functioning with cognitive impairment while they still have the ability to learn how to do this. In addition, the solution includes constant support and management for behavioral change for evidence-based activities that address MCI, such as exercise and mood management. Ultimately, the goal is to give clinicians, patients and family caregivers an effective treatment option and a better quality of life, especially given the dearth of existing pharmacological and non-pharmacological options. Neuroglee offers an end-to-end virtual care solution that includes around-the-clock support by a remote, interdisciplinary care team that includes health coaches and advance practice nurses as well as specialty physicians such as neurologists and neuropsychologists. Neuroglee can be used as a stand-alone digital therapy or in tandem with a prescription drug.
Neuroglee recently concluded a proof-of-concept clinical trial to evaluate the efficacy of its multi-domain intervention for MCI that will be presented to the FDA to support its application for a Breakthrough Designation. Additionally, a significant demonstration of Neuroglee’s economic and clinical ROI is its partnership with Mayo Clinic, which will be officially announced later this year. Neuroglee and Mayo have created a nationwide neuro-rehabilitative solution that provides patients and their families with state-of-the-art, evidence-based, lifestyle and behavioral treatments for MCI. While this is just one use case for Neuroglee’s solution, this partnership clearly signifies trust in the solution to cost-effectively deliver optimal patient outcomes. In addition, other health systems such as Nuvance Health are rolling out Neuroglee’s virtual neurological specialty care program—including technology and an interdisciplinary clinical team—to remotely manage patients living with MCI.
